Guggenheim raised the firm’s price target on Praxis Precision (PRAX) to $800 from $760 and keeps a Buy rating on the shares. The firm’s analysis and feedback from key opinion leaders on ulixacaltamide’s potential penetration in essential tremor supports a potential $15B-plus ET market and a $5B-$10B peak sales range for an effective branded oral, says the analyst, who adds that Praxis remains one of the firm’s Top Picks for 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $510 from $460 at Needham
- Needham Upside Case: Strong Ulixacaltamide Outlook and 2026 Catalyst Stack Drive Praxis Buy Thesis
- Palantir upgraded, Best Buy downgraded: Wall Street’s top analyst calls
- Praxis Precision initiated with an Equal Weight at Wells Fargo
- Praxis Precision price target raised to $1,245 from $340 at H.C. Wainwright